<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3726">
  <stage>Registered</stage>
  <submitdate>4/04/2012</submitdate>
  <approvaldate>4/04/2012</approvaldate>
  <nctid>NCT01574716</nctid>
  <trial_identification>
    <studytitle>Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation. (SOURCE)</studytitle>
    <scientifictitle>A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel in Metastatic Soft Tissue Sarcoma</scientifictitle>
    <utrn />
    <trialacronym>SOURCE</trialacronym>
    <secondaryid>2012-001399-12</secondaryid>
    <secondaryid>MORAb-004-203-STS</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metastatic Soft Tissue Sarcoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Sarcoma (also see 'Bone') - soft tissue</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bone</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - MORAb-004
Treatment: drugs - Gemcitabine
Treatment: drugs - Docetaxel
Treatment: drugs - Gemcitabine
Treatment: drugs - Docetaxel
Treatment: drugs - Placebo

Experimental: MORAb-004, gemcitabine, docetaxel - 

Active Comparator: Placebo, gemcitabine, docetaxel - 


Treatment: drugs: MORAb-004
IV, Days 1 and 8 of every cycle until disease progression

Treatment: drugs: Gemcitabine
IV, Days 1 and 8 of each cycle until disease progression

Treatment: drugs: Docetaxel
IV, Day 8 of every cycle until disease progression

Treatment: drugs: Gemcitabine
IV, Days 1 and 8 of each cycle until disease progression

Treatment: drugs: Docetaxel
IV, Day 8 of every cycle until disease progression

Treatment: drugs: Placebo


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary Objective progression-free survival - To evaluate the progression-free survival (PFS) of subjects treated with the combination of gemcitabine/docetaxel (G/D) plus MORAb-004 versus G/D plus placebo in subjects with metastatic soft tissue sarcoma</outcome>
      <timepoint>Length of study</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary Objective Overall Survival - To assess other clinical parameters
- Overall Survival (OS)
To assess the safety and tolerability of MORAb-004 in combination with gemcitabine and docetaxel
To correlate the pattern of biomarker expression (tumor endothelial marker-1 [TEM-1] and members of the TEM-1 signaling pathway) in tumor samples with observed clinical parameters, including PFS, OS and ORR.</outcome>
      <timepoint>Length of study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Response Rate (ORR) - based on RECIST v 1.1</outcome>
      <timepoint>Length of study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PFS rate (PRF)</outcome>
      <timepoint>at 12, 24 and 48 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Be at least 18 years of age

          -  Be surgically sterile or consent to use a medically acceptable method of contraception
             throughout the study period

          -  Have a histologically confirmed diagnosis of mSTS as defined by the 4 specified study
             subgrouped

          -  Have been treated in the metastatic setting with 0 to 2 prior systemic regimens for
             mSTS (Systemic treatment regimens given in the neoadjuvant setting and maintenance
             therapies will not be considered as regimens in the metastatic setting for the
             purposes of this protocol. Prior anthracycline-based regimen is allowable but not
             required. Subjects with extra-skeletal small round blue cell sarcomas, including
             rhabdomyosarcomas, must have exhausted or be intolerant of standard first line
             anthracycline-based chemotherapy.)

          -  Have measurable disease, as defined by RECIST v 1.1 assess within 2 weeks of study
             entry and have radiologically documented disease progression greater than or equal to
             a 10% increase in the sum of the longest diameters of target lesions present within 6
             months prior to randomization

          -  Have tumor tissue available for TEM-1 biomarker studies

          -  Be willing and able to provide written informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Have received more than 2 prior systemic treatment regimens for mSTS

          -  Have received either gemcitabine or docetaxel in any previous treatment for mSTS
             (regardless of the line of treatment)

          -  Have a diagnosis of primary bone sarcoma of any histological type.

          -  Have a history of clinically significant heart disease, or clinically significant
             arrhythmia on ECG within the past 6 months

          -  Have a history of allergic reaction to prior monoclonal antibody or biologic agent

          -  Have received previous treatment with MORAb-004 (anti-TEM-1)

          -  Have a medical condition with a high risk of bleeding (e.g., a known bleeding
             disorder, a coagulopathy, or a tumor that involves the major vessels) or have a recent
             (within past 6 months) history of a significant bleeding event

          -  Have undergone major surgical procedures or open biopsy, have significant traumatic
             injury within 30 days prior to the first date of study treatment, or have major
             surgical procedures anticipated during the study

          -  Have a serious non-healing wound, an ulcer (including gastrointestinal), or a bone
             fracture</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>209</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,QLD,SA,WA</recruitmentstate>
    <hospital>Canberra Hospital - Garran</hospital>
    <hospital>Royal North Shore Hospital - St. Leonards</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Ashford Cancer Centre Research - Kurralta Park</hospital>
    <hospital>Sir Charles Gairdner Hospital - Perth</hospital>
    <postcode>2605 - Garran</postcode>
    <postcode>2065 - St. Leonards</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>5037 - Kurralta Park</postcode>
    <postcode>6009 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villeurbanne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Leiden</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Morphotek</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is being done to see if MORAb-004 increases the effectiveness of the
      chemotherapies gemcitabine and docetaxel in people with metastatic Soft Tissue Sarcoma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01574716</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Robert G Maki, M.D., FACP</name>
      <address>Icahn School of Medicine at Mount Sinai</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>